FDA Investigator Rebeca M Melendez
Rebeca M Melendez has inspections in 1 countries as of 28 Mar 2023. Rebeca M Melendez has collaborated with a combined 1276 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
8
Last Inspection Date:
28 Mar 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America
Co-Investigator(s):
Abigail A Auster,
Adalberto Cajigas,
Adaliz Santaliz Cruz,
Alan A Rivera,
Angelica M Hernandez,
Ann L Demarco,
Annette Melendez,
Ariel Cruz Figueroa,
Arlene M Badillo,
Arwa S El Hagrasy,
Binh T Nguyen,
Brenda Rivera,
Brian J Ryan,
Carlos A Medina,
Christina Capacci Daniel, PhD,
Dayna I Martinez,
Dennis Cantellops Paite,
Donna Christner,
Edwin Martinez,
German Rivera,
Iraida Ortiz,
Ivis L Negron,
Ivis Lnegron Torres,
Javier O Vega,
Jorge L Gonzalez,
Jorge L Guadalupe,
Jose A Cruz,
Jose A Moreno,
Jose Acruz Gonzalez,
Jose Alopez Rubet,
José E Meléndez,
Jose E Melendez, DDC,
Jose F Pedro,
Jose F Pedró,
Jose Fpedrode Jesus,
Jose Lpez,
Jose Martinez, Jr,
Jose Melendez,
Jose R Lopez,
Jose Velez,
Juan Rjimenez Garcia,
Laura E Garcia,
Laurimer Kuilan Torres,
Libia M Lugo,
Lisa M Lopez,
Lourdes Andujar,
Marian E Ramirez,
Michelle Y Clark Stuart,
Miguel A Martinez,
Miguel Hernandez Sanchez,
Min Tang,
Muralidhara B Gavini, PhD,
Myriam M Sosa,
Noreen Muniz,
Noreen Muñiz,
Pablo Feliciano,
Rafael E Cruz,
Rafael Nevarez,
Rafael Nevarez Nieves,
Ramon A Hernandez,
Raquel Gonzalez,
Raquel Gonzalez Rivera,
Rebecca Parrilla,
Rebecca Rodriguez,
Regina T Brown,
Sharmista Chatterjee,
Sixto M Mercado Rios,
Steven B Barber,
Thomas J Arista,
Vilmary Negron Rodriguez,
Wanda J Torres
Rebeca M Melendez's Documents
Publish Date | Document Type | Title |
---|---|---|
March, 2003 | EIR | Bristol-Myers Squibb Holdings Pharma, Ltd. Liability Company - EIR, 2003-03-13 |
June, 2006 | FDA 483 | Ivax Pharmaceuticals, Inc. - Form 483, 2006-06-02 |
June, 2006 | EIR | Janssen Ortho LLC - EIR, 2006-06-15 |
June, 2017 | FDA 483 | NEOLPHARMA, INC. - Form 483, 2017-06-07 |
March, 2003 | FDA 483 | Bristol-Myers Squibb Holdings Pharma, Ltd. Liability Company - Form 483, 2003-03-13 |
June, 2017 | EIR | NEOLPHARMA, INC. - EIR, 2017-06-07 |
July, 2016 | FDA 483 | AbbVie Ltd - Form 483, 2016-07-29 |
March, 2009 | FDA 483 | Pfizer Pharmaceuticals LLC - Form 483, 2009-03-19 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more